Parallel Advisors’s Serina Therapeutics SER Stock Holding History

Parallel Advisors’s Portfolio SER Stock Details SER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-2	Closed	–	–	2515
2019 Q2	$0	Hold	2	–	–	﹤0.01%	2457
2019 Q1	$0	Buy	+2	New	+$292	﹤0.01%	2413

Other funds holding SER

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Parallel Advisors's SER Position: Q3 2019 in Review

Parallel Advisors sold out of Serina Therapeutics (SER) in Q3 2019, closing a stake of 2 shares.

Parallel Advisors first reported a position in SER in Q1 2019 and held it in 2 quarters. The position peaked at $0 in Q2 2019. 56 funds tracked by Wall St. Rank hold SER as of Q3 2019.

Parallel Advisors reported no remaining Serina Therapeutics position as of Q3 2019 after selling out during the quarter.
Parallel Advisors sold 2 Serina Therapeutics shares in Q3 2019.
Parallel Advisors first reported a position in Serina Therapeutics in Q1 2019 and held it in 2 quarters.
Parallel Advisors's Serina Therapeutics position peaked at $0 in Q2 2019.
56 funds tracked by Wall St. Rank held Serina Therapeutics as of Q3 2019.

Based on Parallel Advisors's 13F filing for Q3 2019, filed 1 Nov 2019.